Ken Fisher’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ken Fisher’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2M	Buy	35,480 +190	+0.5%	+$11.1K	﹤0.01%	574
2025 Q4	$2.1M	Buy	35,290 +3,564	+11%	+$194K	﹤0.01%	552
2025 Q3	$1.72M	Buy	31,726 +18,181	+134%	+$1.04M	﹤0.01%	601
2025 Q2	$745K	Sell	13,545 -28	-0.2%	-$1.65K	﹤0.01%	732
2025 Q1	$960K	Sell	13,573 -393	-3%	-$26.4K	﹤0.01%	686
2024 Q4	$918K	Buy	13,966 +420	+3%	+$28.1K	﹤0.01%	670
2024 Q3	$952K	Buy	13,546 +122	+0.9%	+$10.2K	﹤0.01%	665
2024 Q2	$1.11M	Sell	13,424 -75	-0.6%	-$6.24K	﹤0.01%	668
2024 Q1	$1.18M	Buy	13,499 +9	+0.1%	+$806	﹤0.01%	665
2023 Q4	$1.3M	Buy	+13,490	New	+$1.19M	﹤0.01%	655

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ken Fisher's BMRN Position: Q1 2026 in Review

Ken Fisher increased its BioMarin Pharmaceuticals (BMRN) stake by 0.54% in Q1 2026, buying an estimated $11.1K and bringing the position to 35,480 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #574.

Ken Fisher first reported a position in BMRN in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.1M in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Ken Fisher held 35,480 shares of BioMarin Pharmaceuticals worth $2M as of Q1 2026.
Ken Fisher bought 190 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $11.1K.
BioMarin Pharmaceuticals made up ﹤0.01% of Ken Fisher's portfolio in Q1 2026, its #574 holding.
Ken Fisher first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Ken Fisher's BioMarin Pharmaceuticals position peaked at $2.1M in Q4 2025.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.